Search Results for “COPD” – Page 2 – media

COPD Assessment by CT Analysis

Chronic Obstructive Pulmonary Disease (COPD) is defined as a condition which affects airways and alveoli, leading to the loss of lung function in a progressive manner. COPD is the fourth leading cause of death globally and has affected more than 200 million people throughout the world.
- Source: IndiaTimes
- 2,058
- July 2, 2018
COPD medical device Researches
What is COPD and how is it Treated?

Chronic obstructive pulmonary disease (COPD) is kind of lung disorder where the person may have difficulty in breathing which worsens over time. An irritation or inflammation in the lungs causes the air sacs to lose their elasticity, which leaves the air trapped in the lungs when you exhale. If this lasts too long, it could lead to a group of lung diseases (Chronic bronchitis and Emphysema) known as COPD.
- Source: HealthLine
- 690
- June 19, 2018
Clinical Trials COPD
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.
- Source: us.gsk
- 642
- April 27, 2018
Company Insights COPD FDA GSK
NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GSK is shifting resources towards key therapeutic classes, including respiratory disease.
- Source: fiercepharma.
- 599
- April 24, 2018
Company Insight GSK respiratory disease Trelegy Ellipta
Novartis’ Ultibro Breezhaler reduces lung hyperinflation in COPD patients

Treatment with Novartis’ Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show.
- Source: Pharmatimes
- 607
- February 24, 2018
Company Insight COPD Ultibro Breezhaler
The future of lung function tests for COPD

With the global increase of lung diseases such as asthma, severe bronchitis and emphysema, lung function tests are becoming a bigger concern for many people.
- Source: Ddu
- 1,463
- February 7, 2018
COPD Ddu College Spirometry
AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 586
- January 29, 2018
Clinical Trials COPD inhaler
Starting new COPD inhaler tied to heart attack risk

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
- Source: Reuters
- 525
- January 3, 2018
COPD heart attacks Researches stroke
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 627
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
Rheumatoid arthritis may raise COPD risk

New research suggests that people with rheumatoid arthritis are more likely to develop chronic obstructive pulmonary disease (COPD), which is a group of lung diseases that damage the airways and cause problems with breathing.
- Source: medicalnewstoday
- 548
- October 27, 2017
COPD Researches rheumatoid arthritis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.